IRF6

Across TCGA pan-cancer cohorts, IRF6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IRF6 data layer compared with 20 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IRF6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IRF6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where IRF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.762	0.417	.002	35	view →
PDAC	OS	Tertile	II,III,IV	0.962	0.791	.005	21	view →
UCEC	DFS	Median	All	0.951	0.764	.004	16	view →
LUAD	OS	Tertile	II,III,IV	0.331	1.000	.010	11	view →
LSCC	DFS	Median	II,III,IV	0.963	0.868	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IRF6–CCRCC (DFS)

Open the CCRCC breakdown →